A practical reference on melanocortin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-21. Anything still debated is marked as such rather than presented as settled.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
== Variations == Variants of the azlactone synthesis in which analogues of azlactones are used are sometimes advantageous. Hydantoin (in Bergmann modification), thiohydantoin and rhodanine have each been employed as the enolate-forming component of the condensation.
== History == The law was named after scientist Jacques Charles, who formulated the original law in his unpublished work from the 1780s. In two of a series of four essays presented between 2 and 30 October 1801, John Dalton demonstrated by experiment that all the gases and vapours that he studied expanded by the same amount between two fixed points of temperature. The French natural philosopher Joseph Louis Gay-Lussac confirmed the discovery in a presentation to the French National Institute on 31 Jan 1802, although he credited the discovery to unpublished work from the 1780s by Jacques Charles. The basic principles had already been described by Guillaume Amontons and Francis Hauksbee a century earlier. Dalton was the first to demonstrate that the law applied generally to all gases, and to the vapours of volatile liquids if the temperature was well above the boiling point. Gay-Lussac concurred. With measurements only at the two thermometric fixed points of water (0°C and 100°C), Gay-Lussac was unable to show that the equation relating volume to temperature was a linear function. On mathematical grounds alone, Gay-Lussac's paper does not permit the assignment of any law stating the linear relation. Both Dalton's and Gay-Lussac's main conclusions can be expressed mathematically as:
==== Beverages ==== Carbon dioxide is used to produce carbonated soft drinks and soda water. Traditionally, the carbonation of beer and sparkling wine came about through natural fermentation, but many manufacturers carbonate these drinks with carbon dioxide recovered from the fermentation process. In the case of bottled and kegged beer, the most common method used is carbonation with recycled carbon dioxide. With the exception of British real ale, draught beer is usually transferred from kegs in a cold room or cellar to dispensing taps on the bar using pressurized carbon dioxide, sometimes mixed with nitrogen. The taste of soda water (and related taste sensations in other carbonated beverages) is an effect of the dissolved carbon dioxide rather than the bursting bubbles of the gas. Carbonic anhydrase 4 converts carbon dioxide to carbonic acid leading to a sour taste, and also the dissolved carbon dioxide induces a somatosensory response.
A person, who is independent of the trial, who cannot be unfairly influenced by people involved with the trial, who attends the informed consent process if the subject or the subject's legally acceptable representative cannot read, and who reads the informed consent form and any other written information supplied to the subject. (ICH E6) In vitro
Sources: en.wikipedia.org
=== Advantages === Selective removal: Ion exchange resins can be designed to selectively remove specific ions from water. High efficiency: Ion exchange processes can achieve high removal efficiencies for targeted ions. Regenerability: Ion exchange resins can be regenerated multiple times by flushing them with a regenerating solution, extending their lifespan and reducing operational costs. Versatility: Ion exchange can be applied to various water treatment applications. Consistent performance: Ion exchange systems offer consistent and predictable performance, providing reliable water treatment over time. Scalability: Ion exchange systems can be easily scaled up or down to meet different treatment capacities and requirements.
== Structure == OmpT is a 33.5 kDa outer membrane protein consisting of 10 antiparallel strands that are connected by 5 extracellular loops. The antiparallel strands form a beta barrel structure that spans the width of the membrane, creating a pore. E. coli omptins can be coded either from the OmpT gene on a chromosome (part of a DLP12 prophage) or from OmpP on a plasmid (OmpP). The sequences resulting from these two sources differ by 24-25% in the mature protease. Genetic differences between OmpT and other members of the omptin family are found in the extracellular loops, and therefore, this area is thought to be associated with substrate specificity. Also, the barrel is relatively rigid, while the loops have more flexibility to bind to substrates of varying sizes.
IUPAC recommends the names lanthanoids and actinoids to avoid ambiguity, as the -ide suffix typically denotes a negative ion; however lanthanides and actinides remain common. With the increasing recognition of lutetium and lawrencium as d-block elements, some authors began to define the lanthanides as La–Yb and the actinides as Ac–No, matching the f-block. The transactinides or superheavy elements are the short-lived elements beyond the actinides, starting at lawrencium or rutherfordium (depending on where the actinides are taken to end). Many more categorizations exist and are used according to certain disciplines. In astrophysics, a metal is defined as any element with atomic number greater than 2, i.e. anything except hydrogen and helium. The term "semimetal" has a different definition in physics than it does in chemistry: bismuth is a semimetal by physical definitions, but chemists generally consider it a metal. A few terms are widely used, but without any very formal definition, such as "heavy metal", which has been given such a wide range of definitions that it has been criticized as "effectively meaningless". The scope of terms varies significantly between authors. For example, according to IUPAC, the noble gases extend to include the whole group, including the very radioactive superheavy element oganesson. However, among those who specialize in the superheavy elements, this is not often done: in this case "noble gas" is typically taken to imply the unreactive behaviour of the lighter elements of the group.
The prime recovery ship was USS Wasp. The recovery was supported by 10,249 U.S. Department of Defense personnel, 134 aircraft, and 26 ships. Postflight medical examination found the astronauts to be in good health, and no significant physiological changes were found.
Hyperinsulinemia is a condition in which there are excess levels of insulin circulating in the blood relative to the level of glucose. While it is often mistaken for diabetes or hyperglycaemia, hyperinsulinemia can result from a variety of metabolic diseases and conditions, as well as non-nutritive sugars in the diet. While hyperinsulinemia is often seen in people with early stage type 2 diabetes mellitus, it is not the cause of the condition and is only one symptom of the disease (for opposing view see review in ). Type 1 diabetes only occurs when pancreatic beta-cell function is impaired. Hyperinsulinemia can be seen in a variety of conditions including diabetes mellitus type 2, in neonates and in drug-induced hyperinsulinemia. It can also occur in congenital hyperinsulinism, including nesidioblastosis. Hyperinsulinemia is associated with hypertension, obesity, dyslipidemia, insulin resistance, and glucose intolerance. These conditions are collectively known as metabolic syndrome. This close association between hyperinsulinemia and conditions of metabolic syndrome suggest related or common mechanisms of pathogenicity. Hyperinsulinemia has been shown to "play a role in obese hypertension by increasing renal sodium retention". In type 2 diabetes, the cells of the body become resistant to the effects of insulin as the receptors which bind to the hormone become less sensitive to insulin concentrations resulting in hyperinsulinemia and disturbances in insulin release.
Sources: en.wikipedia.org
=== Synthetic steroids and sterols === A variety of synthetic steroids and sterols have also been contrived. Most are steroids, but some nonsteroidal molecules can interact with the steroid receptors because of a similarity of shape. Some synthetic steroids are weaker or stronger than the natural steroids whose receptors they activate. Some examples of synthetic steroid hormones:
=== SEC-TS === Size exclusion chromatography can be used directly to access protein stability in the presence or absence of ligands. Samples of purified protein are heated in a water bath or thermocycler, cooled, centrifuged to remove aggregated proteins, and run on an analytical HPLC. As the melting temperature is reached and protein precipitates or aggregates, peak height decreases and void peak height increases. This can be used to identify ligands and inhibitors, and optimize purification conditions. While of lower throughput than FSEC-TS, requiring large amounts of purified protein, SEC-TS avoids any influence of the fluorescent tag on apparent protein stability.
=== Even electron rule === The even electron rule states that ions with an even number of electrons (cations but not radical ions) tend to form even-electron fragment ions and odd-electron ions (radical ions) form odd-electron ions or even-electron ions. Even-electron species tend to fragment to another even-electron cation and a neutral molecule rather than two odd-electron species.
== Mechanism of action == Phenazopyridine's mechanism of action is not well known, and only basic information on its interaction with the body is available. It is known that the chemical has a direct topical analgesic effect on the mucosa lining of the urinary tract. It is rapidly excreted by the kidneys directly into the urine. Hydroxylation is the major form of metabolism in humans, and the azo bond is usually not cleaved. On the order of 65% of an oral dose will be secreted directly into the urine chemically unchanged.
=== Novo Nordisk === Thomsen joined Novo Nordisk in 1991 as the head of growth hormone research. In 1994, he was appointed senior vice president of diabetes research & development. In November 2000, he became executive vice president and chief scientific officer, overseeing global operations related to drug and device research, chemistry, manufacturing and controls (CMC), global development, medical affairs, regulatory affairs, and safety. During his tenure, more than 20 pharmaceutical products were developed and approved.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No. Melanotan-2 is manufactured synthetically. The naturally occurring peptide in the same family is alpha-melanocyte-stimulating hormone, which the body produces as part of normal endocrine and neural signalling.